Moderna Inc (LTS:0A45)
$ 39.3575 -1.0175 (-2.51%) Market Cap: 15.50 Bil Enterprise Value: 9.98 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 58/100

Moderna Inc at UBS Global Healthcare Conference Transcript

May 24, 2022 / 01:15PM GMT
Release Date Price: $128.8 (-7.93%)
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

Hi. Good morning, everyone. I'm Ellie Merle. I'm one of the biotech analysts here at UBS. Thank you so much for joining us at the UBS Healthcare Conference in person.

Very happy to have Moderna here with us for a fireside chat. Joining us from Moderna is Lavina Talukdar, SVP, Head of Investor Relations. Thanks so much for joining us here today.

Questions & Answers

Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

I guess to kick it off, high level, you guys have accomplished a lot in the past year or so with mRNA vaccines for COVID-19. Maybe beyond COVID, where do you see mRNA going next?

Lavina Talukdar
Moderna, Inc. - Senior VP & Head of IR

So thanks so much for having me, Ellie, and that is such a great question because we are not just a COVID-19 vaccine company. We have 46 programs in various stages of clinical development.

But having said that, we have demonstrated the power of mRNA and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot